Compare EHang Holdings Ltd - ADR (EH) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Tango Therapeutics Inc. — how do they compare? EHang Holdings Ltd - ADR trades at $3.77 (market cap $289.73M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 12.9× EHang Holdings Ltd - ADR's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 47 Days and Tango Therapeutics Inc. for 0 Days on average.
| EH | TNGX | |
|---|---|---|
Market Cap | $289.73M | $3.75B |
Volume | 749,255 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $18.94 | $32.90 |
52-Week Low | $3.78 | $7.50 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $241.33M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $3.78, down 4.79% on the day, reflecting a bearish technical trend. The company reported revenue of $418 million for 2025 but posted a net loss of $276 million, with negative profit margins and ROE. Recent news includes a law firm investigation into investor claims and expansion of its Global Fast Track Program to Vietnam. Cash flow from operations turned positive in 2024 at $158 million, but investing activities remain heavily negative due to capital expenditures.
The outlook is highly speculative, with significant execution and regulatory risks. Investment opportunity hinges on successful commercialization of eVTOL technology, but persistent losses and bearish analyst sentiment suggest caution. Key risks include ongoing legal scrutiny, intense competition, and reliance on future regulatory approvals for growth.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
